Post-marketing effectiveness of Prevnar [pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein)] and implications for adult immunization

Betsy Abraham-Van Parijs; Frank J Malinoski

doi:10.1016/j.mad.2003.12.001

Post-marketing effectiveness of Prevnar [pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein)] and implications for adult immunization

Mech Ageing Dev. 2004 Feb;125(2):147-8. doi: 10.1016/j.mad.2003.12.001.

Authors

Betsy Abraham-Van Parijs¹, Frank J Malinoski

Affiliation

¹ Wyeth Pharmaceutical, 500 Arcola Rd., Collegeville, PA 19426, USA.

PMID: 15037021
DOI: 10.1016/j.mad.2003.12.001

Abstract

Pneumococcal pneumonia is a significant health concern for pediatric, healthy adult, and elderly populations. The newly licensed pneumococcal 7-valent conjugate (diphtheria CRM197 protein) vaccine, Prevnar, and a second generation experimental 9-valent product have demonstrated, for the first time, a clear and significant impact on pneumococcal pneumonia in children. The potential for saccharide-conjugate vaccines to help prevent pneumococcal pneumonia in adult and elderly populations and potential barriers to the introduction of a conjugate vaccine in adults are discussed.

Publication types

Review

MeSH terms

Adult
Heptavalent Pneumococcal Conjugate Vaccine
Humans
Meningococcal Vaccines / therapeutic use*
Pneumococcal Vaccines / therapeutic use*
Pneumonia, Pneumococcal / prevention & control*
Product Surveillance, Postmarketing*
Vaccines, Conjugate / therapeutic use*

Substances

Heptavalent Pneumococcal Conjugate Vaccine
Meningococcal Vaccines
Pneumococcal Vaccines
Vaccines, Conjugate